SCIENCE NEWS PARP Inhibitor, MK-4827, Shows Anti-Tumour Activity in First Trial in Humans A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans. Some patients with a range of solid tumours, many of whom had been treated unsuccessfully for their cancer with other therapies, have seen their tumours shrink or stabilise for periods of between 46 days to more than a year. [Press release from the European CanCer Organization (ECCO) discussing data presented at the 22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium on Molecular Targets and Cancer Therapeutics] Detecting Cancer With the Prick of a Finger Researchers have created a micro device that could both decrease the amount of blood and time needed to test for cancer-markers in a patient’s blood. [Press release from Brigham Young University discussing online prepublication in Lab on a Chip]
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH Biological Activity of 4-Substituted Methoxybenzoyl-Aryl-Thiazole (SMART): An Active Microtubule Inhibitor Researchers recently reported a class of 4-Substituted Methoxybenzoyl-Aryl-Thiazoles (SMART) that exhibited great in vitro potency and broad spectrum cellular cytotoxicity. Evaluation of the in vitro and in vivo anti-cancer activities of three SMART compounds, SMART-H (H), SMART-F (F) and SMART-OH (OH) with varying substituents at the 4-position of aryl ring, demonstrated that they bind potently to the colchicine binding site in tubulin, inhibit tubulin polymerization, arrest cancer cells in G2/M phase of the cell cycle, and induce their apoptosis. [Cancer Res] The BH3 Mimetic ABT-737 Induces Cancer Cell Senescence ABT-737, a small molecule cell-permeable Bcl-2 antagonist that acts by mimicking BH3 proteins, induces apoptotic cell death in multiple cancer types. However, when incubated with this agent many solid tumor cell lines do not undergo apoptosis. The current study reveals a novel mechanism whereby ABT-737 when added to apoptosis-resistant cancer cells has profound biologic effects. [Cancer Res] The Bcl-2-Beclin 1 Interaction in (-)-Gossypol-Induced Autophagy Versus Apoptosis in Prostate Cancer Cells The results provide new insights into the mode of cell death induced by Bcl-2 inhibitors, which could facilitate the rational design of clinical trials by selecting patients who are most likely to benefit from the Bcl-2-targeted molecular therapy. [Autophagy] Microdevices Integrating Affinity Columns and Capillary Electrophoresis for Multibiomarker Analysis in Human Serum Here, researchers developed integrated microdevices with an affinity column and capillary electrophoresis channels to isolate and quantitate a panel of proteins in complex matrices. [Lab Chip] Proteomics Profiling of Microdissected Low- and High-Grade Prostate Tumors Identifies Lamin A as a Discriminatory Biomarker Researchers used two-dimensional differential gel electrophoresis in combination with laser capture microdissection and MALDI-TOF/TOF mass spectrometry to determine differentially abundant proteins and candidate biomarkers in prostate cancer. [J Proteome Res] Neuroendocrine Prostate Cancer Xenografts With Large-Cell and Small-Cell Features Derived From a Single Patient’s Tumor: Morphological, Immunohistochemical, and Gene Expression Profiles Eight tumor fragments from the salvage pelvic exenteration specimen of a patient with castrate-resistant prostate carcinoma were subcutaneously implanted into 6- to 8-week-old male CB17 SCID mice. Serial tissue sections and tissue microarrays of the resulting MDA PCa 144 xenograft lines were used for histopathologic and immunohistochemical characterization of the xenografts and their tissue of origin. [Prostate] Selenoprotein-P is Down-Regulated in Prostate Cancer, Which Results in Lack of Protection Against Oxidative Damage The main goal of the study was to assess whether selenoprotein-P protects prostate cells from reactive oxygen species in prostate carcinogenesis. [Prostate] CLINICAL RESEARCH Disease and Host Characteristics as Predictors of Time to First Bone Metastasis and Death in Men with Progressive Castration-Resistant Nonmetastatic Prostate Cancer In men with progressive castration-resistant prostate cancer and no detectable metastases, baseline prostate-specific antigen (PSA) was significantly associated with time to first bone metastasis, bone metastasis-free survival, and overall survival. [Cancer] Risk of Prostate Cancer is Not Associated With Levels of C-Reactive Protein and Other Commonly Used Markers of Inflammation Most population-based studies studied the association between inflammation and prostate cancer by assessing C-reactive protein. Since these findings have shown inconsistent results, researchers aimed to also study different markers that have been commonly taken as indications of inflammation. [Int J Cancer]
|
EVENTS (Listed by Date) Cancer Pharmacogenetics: Personalizing Medicine November 22-24, 2010 Madrid, Spain American Association for Cancer Research (AACR) Tumor Immunology – Basic and Clinical Advances November 30-December 3, 2010 Miami, United States 5th Annual Stem Cell Meeting on the Mesa December 7, 2010 La Jolla, United States 11th Annual Meeting of the Society of Urologic Oncology (SUO): Extraordinary Opportunities for Discovery December 8-9, 2010 Bethesda, United States The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine December 17-19, 2010 Guangzhou, China American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer February 24-27, 2011 San Francisco, United States American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer March 3-6, 2011 Vancouver, Canada MENA Oncology Conference March 11-12, 2011 Cairo, Egypt The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics March 16-19, 2011 Las Vegas, United States United Kingdom National Stem Cell Network 2011 Annual Scientific Conference March 30-April 1, 2011 York, United Kingdom American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 April 2-6, 2011 Orlando, United States International Society for Stem Cell Research (ISSCR) 9th Annual Meeting June 15-18, 2011 Toronto, Canada National Cancer Institute (NCI) Cancer Research Imaging Camp June 19-24, 2011 St. Louis, United States 4th Annual Advances in Biodetection & Biosensors Conference and Exhibition June 30-July 1, 2011 Hamburg, Germany Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community. JOB OPPORTUNITIES Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies) Lab Technologist – Tissue Culture (STEMCELL Technologies) Product Manager – Pluripotent Stem Cells (STEMCELL Technologies) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost. Visit here to post your career opportunities.
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or Suggestions? Email info@connexoncreative.com with your feedback. |
|
|